## Clinical Context This is a screening scenario where an asymptomatic woman with a palpable breast nodule has been identified. The key issue is determining whether this lesion requires tissue diagnosis. ## Diagnostic Approach to Palpable Breast Nodules **Key Point:** In screening settings, any palpable nodule in an asymptomatic woman requires tissue diagnosis to exclude malignancy, regardless of normal imaging. **High-Yield:** The triple assessment approach (clinical examination + imaging + tissue diagnosis) is the gold standard for evaluating breast lesions. When imaging is discordant with clinical findings (normal mammography but palpable mass), tissue diagnosis becomes mandatory. ## Why Core Needle Biopsy? | Feature | FNAC | Core Needle Biopsy | |---------|------|-------------------| | Diagnostic accuracy | 85–90% | 95–98% | | Tissue architecture | Not preserved | Preserved | | Ability to subtype lesions | Limited | Excellent | | Recommended for palpable masses | No | Yes | | Can differentiate benign from malignant | Moderate | High | **Clinical Pearl:** FNAC has a higher inadequacy rate (10–15%) and lower specificity for palpable lesions. Core needle biopsy (14G or 16G) is preferred because it: - Provides histological architecture - Allows accurate subtyping (invasive vs. in situ carcinoma) - Has minimal false-negative rate (<2%) - Is minimally invasive and can be done as outpatient procedure **Key Point:** Normal mammography does NOT exclude malignancy in a palpable nodule, especially in younger women with dense breast tissue. Ultrasound-guided core biopsy is the next appropriate step to obtain definitive tissue diagnosis. ## Screening Principle Screening aims to identify disease in asymptomatic individuals. Once a lesion is detected, it transitions from screening to diagnostic evaluation, and diagnostic standards apply.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.